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Essentials
• Plasma-derived factor X concentrate (pdFX) is used to treat hereditary factor X deficiency.
• pdFX pharmacokinetics, safety and efficacy were assessed in factor X-deficient women/girls.
• Treatment success rate was 98%; only 6 adverse events in 2 subjects were possibly pdFX related.
• On-demand pdFX 25 IU kg À1 was effective and safe in women/girls with factor X deficiency.
Summary. Background: A high-purity, plasma-derived factor X concentrate (pdFX) has been approved for the treatment of hereditary FX deficiency, an autosomal recessive disorder. Objective: To perform post hoc assessments of pdFX pharmacokinetics, safety and efficacy in women and girls with hereditary FX deficiency. Patients/ Methods: Subjects aged ≥ 12 years with moderate/severe FX deficiency (plasma FX activity of < 5 IU dL À1 ) received on-demand or preventive pdFX (25 IU kg À1 ) for ≤ 2 years. Results: Of 16 enrolled subjects, 10 women and girls (aged 14-58 years [median, 25.5 years]) received 267 pdFX infusions. Mean monthly infusions per subject were higher among women and girls (2.48) than among men and boys (1.62). In women and girls, 132 assessable bleeding episodes (61 heavy menstrual bleeds, 47 joint bleeds, 15 muscle bleeds, and nine other bleeds) were treated with pdFX, with a 98% treatment success rate versus 100% in men and boys. Mean pdFX incremental recovery was similar in the two groups (2.05 IU dL À1 versus 1.91 IU dL À1 per IU kg À1 ), as was the mean half-life (29.3 h versus 29.5 h). Of 142 adverse events in women and girls, headache was the most common (12 events in six subjects). Six events (two infusion-site erythema, two fatigue, one back pain, one infusion-site pain) in two subjects were considered to be possibly pdFX-related. Following the trial, pdFX was used to successfully maintain hemostasis in two subjects undergoing obstetric delivery. Conclusions: pdFX was well tolerated and effective in women and girls with FX deficiency. Although women
Introduction
Hereditary factor X deficiency is an extremely rare autosomal recessive disease, with a prevalence of 1 : 500 000 to 1 : 1 000 000 in the general population [1, 2] . As FX plays a central role in the blood coagulation pathway by cleaving prothrombin into active thrombin, FX-deficient patients are affected by particularly severe symptoms (i.e. gastrointestinal bleeding or life-threatening umbilical stump bleeding), and frequently suffer from bleeding into joints, muscles, or mucous membranes [1] [2] [3] . In addition to these general bleeding symptoms, women and girls with FX deficiency also experience heavy menstrual bleeding and postpartum hemorrhage that can reduce their quality of life [3, 4] . Therapeutic options for the management of hereditary FX deficiency have historically included fibrinolytic inhibitors, fresh-frozen plasma (FFP), and prothrombin complex concentrates (PCCs) [5, 6] . In addition, women and girls with FX deficiency are often treated with hormonal contraceptives to manage heavy menstrual bleeding, and some even undergo hysterectomy or endometrial ablation to relieve such bleeding [4] . A high-purity, high-potency, plasma-derived FX concentrate (pdFX) (Bio Products Laboratory, Elstree, UK) was recently developed for ondemand treatment and the control of bleeding episodes in patients with hereditary FX deficiency [7] . The efficacy and safety of pdFX have been demonstrated in five subjects with mild-to-severe (defined as FX activity [FX: C] of <20 IU dL À1 ) hereditary FX deficiency undergoing surgery [8] and in a phase 3 trial of 16 subjects with moderate-to-severe (FX:C < 5 IU dL À1 ) hereditary FX deficiency receiving on-demand or preventive treatment [9] . The latter study (N = 16) also demonstrated that the pharmacokinetic characteristics of pdFX were consistent with the observed hemostatic efficacy of pdFX as well as with other coagulation factors used as replacement therapy in patients with inherited bleeding disorders [10] . As women and girls represented almost two-thirds of the study population and suffered from severe and frequent clinical symptoms, this post hoc analysis describes pdFX use in women and girls enrolled in the phase 3 trial of pdFX efficacy, pharmacokinetics, and safety [9] .
Methods

Study design
This was a post hoc analysis of women and girls enrolled in an open-label, multicenter, non-randomized phase 3 study of pdFX in subjects with moderate or severe hereditary FX deficiency (ClinicalTrials.gov, NCT00930176; EudraCT identifier, 2009 0111145-18) [9] . Study centers were located in the USA, the UK, Spain, Germany, and Turkey. The study protocol was approved by each center's local or national independent ethics committee. The study was conducted between February 2010 and October 2013 in accordance with Good Clinical Practice Guidelines [11] , and written informed consent was obtained from all subjects prior to study participation.
Full details of this study design have been published previously [9] . Briefly, following screening, subjects received on-demand pdFX treatment for ≥ 6 months but for < 2 years and until one or more bleeds had been treated with pdFX. A pdFX dose of 25 IU kg À1 (to the nearest 1 mL) was selected for treatment of bleeds, and infused at a rate of ≤ 20 mL min
À1
; the treatment was repeated as necessary until hemostasis was achieved. In the case of heavy menstrual bleeding, hemostasis was achieved when bleeding was maintained at a manageable level (i.e. with no significant limitation on normal activities). All bleeds were treated either at home or at the study site, with the exception of the first infusion, which was administered at the study site. Infusions of pdFX to treat heavy menstrual bleeding could be given up to 1 day prior to commencement of bleeding, and were classified as on-demand treatment. The use of pdFX was also permitted as short-term preventive therapy (e.g. prior to dental treatment or sporting activity) and as presurgical prophylaxis [8] .
Subjects
Eligible subjects were aged ≥ 12 years, had moderate or severe FX deficiency (FX:C < 5 IU dL À1 ), and had experienced one or more spontaneous bleeds or bleeds attributable to heavy menstruation in the previous 12 months requiring treatment with FFP, PCC, or an factor IX/X concentrate. Subjects were excluded if they had a history of FX inhibitor development, tested positive for FX inhibitors at screening, or were thrombocytopenic. Subjects were also excluded if they had clinically significant renal disease (serum creatinine level of > 200 lmol L
À1
) or liver disease (serum alanine aminotransferase levels greater than three times the upper normal limit), or had another coagulopathy or known thrombophilia. The use of antifibrinolytics was to be minimized if possible, but was permitted during the study. Women and girls receiving hormonal contraceptives for the treatment of heavy menstrual bleeding should have been on a stable dose regimen for at least 3 months prior to study entry and be planning to remain on a stable dose regimen.
Assessments
The efficacy, pharmacokinetics and safety assessments for pdFX have been published previously [9, 10] . In brief, subjects evaluated the efficacy of the treatment of each bleed, and investigators evaluated treatment efficacy for any bleeds assessed during visits to the investigational site. Investigators also assessed overall pdFX efficacy in all bleeds and prophylactic doses at each subject's study completion. Bleeds were categorized as heavy menstrual bleeding, overt bleeding (e.g. epistaxis, tongue/gingival bleeds, hematemesis, hematuria, rectal bleeding, or external traumatic bleeding), or covert bleeding (e.g. joint bleeds, muscle bleeds, intracranial hemorrhage, hematoma/bruising, melena, or internal traumatic bleeding). For each bleed, pdFX efficacy was assessed as 'excellent', 'good', 'poor', or 'unassessable' [9] . An independent data review committee comprising three hemophilia experts determined whether each bleed would be included in the efficacy assessment. A bleed was excluded from the efficacy assessment if information was insufficient and/or protocol deviations were present. Each bleed was also characterized as major or minor by the data review committee to avoid site-specific biases in this assessment. The following general principles were agreed upon by the committee: major bleeds included severe gastrointestinal bleeding, intracerebral hemorrhage, severe hemarthrosis, and large and/or complicated muscle hematoma; minor bleeds included epistaxis, gingival bleeding, mild menstrual bleeding, and superficial hematoma. The decision on whether to include each bleed in the efficacy assessment was made after taking all data into account (e.g. bleed duration, treatment with pdFX and other hemostatic agents, and comments from the investigator).
Pharmacokinetic assessments were performed in all subjects at baseline and at 6 months, or after one or more bleeds had been treated with pdFX. At each pharmacokinetic assessment, blood samples were taken predose and at 0.25, 0.5, 1, 3, 6, 24, 48, 72, 96, 120 and 144 h following a pdFX dose of 25 IU kg À1 . The FX assay was performed at a central laboratory (Haematology Department, Addenbrooke's Hospital, Cambridge, UK). A one-stage clotting assay based on the prothrombin time was used, with HemosIL RecombiPlasTin 2G (human recombinant tissue factor). Pharmacokinetic parameters were derived from individual (predose-adjusted) plasma concentration versus time profiles of FX:C, and pharmacokinetic parameters were calculated with a non-compartmental approach with WINNONLIN PHOENIX version 6.4. Safety was assessed in all subjects who received one or more doses of pdFX during the study. Safety and tolerability assessments included adverse events (AEs), thrombogenicity markers (thrombin-antithrombin complex, Ddimer, and prothrombin fragment 1 + 2), and viral serology (HIV, hepatitis A virus, hepatitis B virus, hepatitis C virus, and parvovirus B19). The development of FX inhibitors, which was tested every 3 months throughout the study, was analyzed with activated partial thromboplastin time-based inhibitor screens and a Nijmegen-Bethesda assay. In addition, reactions at the infusion site were assessed predose and immediately prior to each postdose pharmacokinetic blood sample collection. After study completion, treating physicians provided data on subjects who received pdFX as hemostatic cover for obstetric delivery.
Results
Subject demographics and characteristics
The phase 3 study enrolled 16 subjects (aged 12-58 years [median, 20 years] [9] ), including 10 (62.5%) women and girls, who were included in this analysis (Table 1) . Women and girls had a median age of 25.5 years (range, 14-58 years) and a mean time from diagnosis to study entry of 22.2 years (standard deviation [SD] 14.7 years) (as compared with 18.1 years [SD 3.6 years] for men and boys). In accordance with FX:C levels measured prior to and at screening for the study, nine women and girls and five men and boys had severe FX deficiency, and one subject in each cohort had moderate FX deficiency. Prior to study enrollment, nine women and girls had received extensive treatment (> 100 exposure days) with factor concentrates (PCCs or Factor X P Behring [FIX/X concentrate; CSL Behring, Marburg, Germany]), whereas one subject had received no previous treatment with replacement factor concentrates but had > 150 exposure days of FFP. Additionally, the majority of women and girls (80%) had a history of heavy menstrual bleeding, and almost half of the cohort (40%) had a history of anemia. In the year prior to study entry, half of women and girls with a history of heavy menstrual bleeding had at least one bleed treated with a replacement factor concentrate. In the subjects' lifetimes, heavy menstrual bleeding was treated with hormonal contraceptives (n = 5 [62.5%]), blood transfusion (n = 5 [62.5%]), antifibrinolytics (n = 4 [50.0%]), or iron therapy (n = 4 [50.0%]), and two subjects (subjects 1 and 5) continued to receive hormonal contraceptives as treatment for such bleeding after study enrollment. Subject 1 had been taking ethinylestradiol and norgestimate since August 2005, and continued to take these throughout the study. While in the study, she had three episodes of heavy menstrual bleeding, one of which was serious enough for her to be admitted to the hospital for treatment of this bleeding and dysmenorrhea. Subject 5 took drospirenone with ethinylestradiol from August 2009 until November 2011, and then switched to levonorgestrel with ethinyl estradiol and continued to take these throughout the study. During the study, she had one episode of heavy menstrual bleeding. Subject 9 had been taking estradiol and norgestrel from January 2007 until June 2012, shortly before her screening visit. This subject experienced 13 episodes of heavy menstrual bleeding during the study. All but one of these bleeds were considered to be minor, but the subject was treated at the study center on each occasion with one or two infusions of pdFX.
In the women and girls cohort (n = 10), three subjects used tranexamic acid during the study for a total of nine episodes: one tooth extraction and eight bleeding episodes ( Table 2 ). All treatments with antifibrinolytics were short term and did not differ appreciably from those used in men and boys. Of the 187 bleeds treated with pdFX in the efficacy analysis of the overall cohort, eight bleeds (4.3%) were also treated with tranexamic acid (Table 3) , all in the women and girls cohort.
Nine of the 10 women and girls completed the study. One subject, aged 58 years, died from bilateral pneumonia complicated by a nosocomial infection, judged by the investigator to be unrelated to pdFX, shortly after the 1-month study visit [9] .
Hemostatic efficacy
In the women and girls cohort, the median number of bleeds per subject per month was 0.98 (range, 0.2-3.6). A total of 149 bleeds (range, 2-59) in the 10 women and girls were treated with pdFX (Fig. 1 ). Of these, 132 pdFX-treated bleeds were selected by the data review committee for inclusion in the primary efficacy analysis.
Approximately half of these assessed bleeds were mucosal (n = 63), and, of these, 61 bleeds in seven subjects were attributable to heavy menstrual bleeding ( Fig. 2A) . All remaining bleeds were covert (n = 67) or overt (n = 4). The majority of bleeding episodes (55.3%) were reported as major bleeds, with the remainder being categorized as minor bleeds (43.9%) or unknown (0.8%) ( Table 3) . Subject 10, who was diagnosed with moderate FX deficiency at enrollment, had the highest frequency of bleeds during the study. As severity of FX deficiency was categorized according to FX:C values, the investigator later considered the assignment of this subject to the moderate group to have been an artefact of the level of FX:C determined This subject had 12 assessable bleeds (treated with pdFX), of which six were also treated with tranexamic acid: two spontaneous muscle bleeds, one spontaneous joint bleed, one spontaneous gum bleed, one heavy menstrual bleed, and one traumatic joint bleed 7 2 This subject took tranexamic acid on two occasions for heavy menstrual bleeds that were also treated with pdFX, as the tranexamic acid was insufficient 10 1 This subject had the highest number of bleeds in the study, but did not use tranexamic acid for treatment of her bleeds. She used tranexamic acid mouthwash 250 mg on 12 occasions following a multiple tooth extraction, for which a presurgical prophylactic pdFX dose of 45 IU/kg was given pdFX, plasma-derived factor X concentrate. This subject had no assessable bleeds, owing to the administration of other FX-containing products. NA, not applicable.
at the local laboratory. The subject's F10 genotype and bleeding diathesis were consistent with a severe bleeding deficiency.
A total of 267 pdFX infusions (266 exposure days) were administered in the women and girls cohort (178 for ondemand treatment and 89 for preventive treatment), with a total dose of 490 505 IU (6841 IU kg À1 ) being administered. Of 89 preventive infusions, 27 were administered prior to increased physical activity (e.g. sports). For the 62 remaining preventive infusions, other reasons for preventive treatment included routine prophylaxis, dental cleaning, treatment to prevent further gastrointestinal rectal rebleeding or hematuria, and heavy menstrual bleeding. For total use, the mean number of infusions per subject per month was higher for women and girls (2.48) than for men and boys (1.62), who received a total of 159 pdFX infusions (64 on-demand and 95 preventive). Table 4 summarizes the pdFX infusions received by women and girls. For treatment of bleeds, women and girls received a mean of 1.58 infusions per subject per month, as compared with 0.65 infusions per subject per month for men and boys. On the basis of the total dose of 4538 IU kg À1 used to treat 149 bleeds in women and girls, an average of 30.5 IU kg À1 pdFX was used per bleed. After exclusion of data from subject 10, who reported an unusually high frequency of bleeds, the total dose used to treat bleeds was 2720 IU kg À1 , and an average of 30.2 IU kg
À1
was used per bleed. Assessable bleeds attributable to heavy menstrual bleeding (n = 61) were treated with 76 infusions, two of which were given before bleeding commenced. The mean number of infusions per bleed attributable to heavy menstrual bleeding was 1.25 (range, 1-3 ). Figure 2B summarizes the assessable bleeds attributable to heavy menstrual bleeding that were treated with pdFX by the number of infusions required to treat a bleed.
Of 132 bleeds treated with pdFX and included in the assessment of efficacy among women and girls, subjects assessed pdFX efficacy as 'excellent' for 116 bleeds (87.9%) and 'good' for 13 bleeds (9.8%); pdFX efficacy in the remaining three bleeds was rated as 'poor' (n = 2) or 'unassessable' (n = 1). This resulted in a treatment success rate (i.e. 'excellent' or 'good' response) of 98%, which is comparable to the 100% treatment success rate among men and boys. For the nine women and girls who completed the study, the investigator rated the assessment of pdFX efficacy in all of its uses (on-demand, preventive, and/or surgical) as 'excellent' in six subjects (66.7%) and 'good' in three subjects (33.3%).
Among women and girls, pharmacokinetic parameters of FX:C (clotting) following single intravenous doses of pdFX were comparable at the baseline (n = 10) and repeat (n = 9) pharmacokinetic assessment visits; therefore, pharmacokinetic parameters from both visits were combined (n = 19) to obtain summary pharmacokinetic values. The mean pdFX incremental recovery was similar in women and girls 
Safety and tolerability
Of the 142 treatment-emergent AEs reported in the 10 women and girls, the majority (95.1%) were mild or moderate in severity. The most frequently reported treatmentemergent AE was headache (12 events in six subjects).
The following six events in two women and girls were considered to be possibly related to pdFX: fatigue (two events), infusion-site erythema (two events) and back pain (one event) in one subject, and infusion-site pain (one event) in another subject. No pdFX-related AEs were observed in men and boys. No AEs were considered to be probably or very probably related to pdFX treatment.
One subject died as a result of two serious AEs (bilateral pneumonia and nosocomial infection) that were judged by the investigator to be unrelated to study treatment.
No subject developed inhibitors against FX; no viral seroconversions or hypersensitivity reactions to pdFX were observed; and no thrombotic events or clinical signs of thrombogenicity were reported.
Post-trial experience of pdFX in pregnancy
Following the trial, two pregnancies were documented in subject 10 (Bio Products Laboratory, data on file). At age 17 years, the patient, who was taking a twice-weekly pdFX dose of 1500 IU (23 IU kg À1 ), reported a spontaneous abortion at 6 weeks and 3 days and underwent curettage. The treating gynecologist noted, at the time of the spontaneous abortion, that b-human chorionic gonadotropin levels were low, indicating that the pregnancy was not intact prior to the abortion, and that the bleeding was therefore a consequence and not a cause of the abortion. The patient reported three subsequent spontaneous abortions; however, these were not confirmed by gynecological examination. Less than 2 years after the first spontaneous abortion, the patient reported another pregnancy. The frequency of pdFX treatment (1500 IU) was increased from twice weekly to three times weekly in an attempt to protect the pregnancy, and because the patient had reported nose bleeds. At 20 weeks and 6 days, FX incremental recovery was 2.57 IU dL À1 per IU kg À1 , which was similar to the results obatined during the clinical trial. Spontaneous labor commenced at 39 weeks and 5 days, 2 days after the previous routine dose of pdFX. One additional dose of 1500 IU of pdFX was administered for the delivery, which was spontaneous and did not require assistance. No bleeding complications occurred during the delivery of the baby and placenta, no delay occurred in delivery of the placenta, and postpartum bleeding was not excessive. However, lochia was increased as compared with a patient without a bleeding disorder. The baby was healthy, with no reported bleeding diathesis. Three weeks after delivery, the patient returned to the twice-weekly dosing regimen.
Also following the trial, subject 9 reported a pregnancy, during which she was given two doses of 1500 IU of pdFX for spontaneous mucosal bleeds. The subject was given 1500 IU (18.8 IU kg
À1
) of pdFX as prophylaxis 2 days before the full-term delivery of her second child (Bio Products Laboratory, data on file). On the day of delivery, 4 units of FFP were given to the patient (pdFX was not available at that time). No excessive bleeding was recorded during the delivery of the baby and placenta. After delivery, the subject was given 1500 IU of pdFX to treat a postpartum bleed lasting for 4 days, and subsequently received three further onceweekly doses of 1500 IU of pdFX, before resuming an on-demand treatment regimen. No other hemostatic agents were used during the delivery.
Discussion
This post hoc analysis assessed the efficacy, pharmacokinetics and safety of pdFX in women and girls with moderate or severe hereditary FX deficiency. Although one subject (subject 10) was categorized as having moderate FX deficiency at study enrollment, this subject had the highest frequency of bleeds during the study, and the investigator later considered the assignment of this subject following single intravenous doses of plasma-derived factor X concentrate were comparable at the baseline (n = 10) and repeat (n = 9) pharmacokinetic assessment visits; therefore, pharmacokinetic parameters from both visits were combined (n = 19) to obtain summary pharmacokinetic values.
to the moderate group to have been attributable to the level of FX:C determined at the local laboratory. All women and girls completed the study, except for one subject who died from AEs unrelated to pdFX. In this analysis, women and girls reported a treatment success rate of 98%, which is comparable to the 100% treatment success rate among men and boys, and pdFX was efficacious against both spontaneous bleeding and bleeding attributable to injury or heavy menstruation. Following single intravenous doses of pdFX, mean pdFX incremental recovery was similar among women and girls and among men and boys, and mean half-life was also similar in each cohort. Of the 267 pdFX infusions administered to women and girls, only six AEs in two subjects were considered by the investigator to be possibly related to treatment. These possibly related events were infusionsite erythema (two events in two subjects), back pain (one event in one subject), fatigue (two events in one patient), and infusion-site pain (one event in one subject).
Women and girls constituted two-thirds of all subjects enrolled in this phase 3 study of patients with moderate or severe hereditary FX deficiency. Although few studies have been published describing the relative proportions of women and girls versus men and boys with hereditary FX deficiency, the ratio observed in this study is not unusual among studies of rare bleeding disorders [12] . Among these women and girls with moderate or severe hereditary FX deficiency, the observed symptoms of heavy menstrual bleeding, joint and muscle bleeds, epistaxis, gingival bleeding and bleeding caused by external trauma are similar to those previously reported in women and girls with FX deficiency [1, 3] .
A thorough evaluation to rule out rare bleeding disorders, including FX deficiency, should be performed in all women and girls with heavy menstrual bleeding. Although the majority of women and girls in this study experienced such bleeding (80%), none of the subjects reported having undergone a hysterectomy because of bleeding. Other than replacement factor concentrates, heavy menstrual bleeding was most commonly treated prior to study enrollment with hormonal contraceptives or blood transfusion; however, in some societies and/or cultures, hormonal contraceptives may not be available as a treatment option for some women [13] .
After the study, pdFX was administered to two subjects undergoing obstetric delivery to maintain hemostasis. Neither subject experienced bleeding complications during delivery. However, one subject experienced postpartum bleeding, which was treated with one dose of pdFX followed by three once-weekly doses of pdFX.
Although a variety of therapeutic options exist for FXdeficient women and girls, pdFX is the only specific factor concentrate that has been developed for the treatment of hereditary FX deficiency. For women and girls with FX deficiency, who are disproportionately symptomatic owing to their reproductive tract bleeding, pdFX confers the advantage of specific replacement and treatment for a deficiency state as compared with fibrinolytic inhibitors or PCCs, and avoids the potential infectious and allergic risks associated with FFP [1] . Because this disorder is rare in the general population, this post hoc analysis is limited by a small sample size of patients with severe FX deficiency; however, this analysis remains important, as it provides valuable information on the symptoms and required treatment for this vulnerable population. Despite the small sample size, these results demonstrate that pdFX was efficacious and safe in women and girls with moderate or severe hereditary FX deficiency for prophylactic and on-demand treatment of bleeding episodes at a dose of 25 IU kg
À1
, as well as for treatment during pregnancy and the peripartum period. Biologics; speakers' bureau participant for Biogen; member of the International Network for Pediatric Hemophilia funded by Bayer HealthCare; member of the Novo Nordisk
